Opinion|Videos|October 18, 2024
Biomarker Discovery and Exploration for SCLC
Key Takeaways
- Biomarker testing in SCLC is essential for personalizing treatment, though less established than in non-small cell lung cancer.
- Testing is usually incorporated at diagnosis or during disease progression to guide therapeutic decisions.
Panelists discuss how biomarker testing is currently utilized in the management of patients with small cell lung cancer (SCLC), including its timing within the treatment journey, while also exploring the existing unmet needs in biomarker testing for SCLC and potential strategies to address and overcome these challenges in the future.
Advertisement
Episodes in this series
What is the role of biomarker testing in your patients with small cell lung cancer (SCLC)? When in their treatment journey do you incorporate it?
What are the current unmet needs with biomarker testing in SCLC, and how can they be addressed and overcome in the future?
Advertisement
Related to this article
AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.
A home-based oncology model using clear bagging is transformational for practices, protecting Medicare reimbursement and provider control, while lowering costs for patients, providers and payers
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.
Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
Machine Learning Has High Accuracy, Little Prospective Validation in MPNs
3
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
4
The Next Decade of Cancer Care Is Coming Home: Who Will Be in the Driver’s Seat?
5